Differential expression and activation of NF-κB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection by Mishra, Alok et al.
Differential expression and activation of NF-jB family proteins during oral
carcinogenesis: Role of high risk human papillomavirus infection
Alok Mishra1, Alok C. Bharti1, Prishla Varghese1, Daman Saluja2 and Bhudev C. Das1*
1Division of Molecular Oncology, Institute of Cytology and Preventive Oncology (ICMR), I-7, Sector-39, Noida 201301, India
2Laboratory of Medical Biotechnology, Ambedkar Centre for Biomedical Research, University of Delhi, Delhi 110 007, India
Oral cancer is one of the most common cancers in India and
south-east Asian region consisting of more than 50% of all ma-
lignant tumors. Along with many known risk factors, infection
of Human Papillomavirus (HPV) has been associated with the
development of oral cancer and is suggested to modulate host
cell transcription. Reciprocally, cellular transcription factors,
such as NF-jB and AP-1 are known to modulate the expression
of viral and other genes involved in the development of cancer.
In the absence of data on NF-jB in relation to HPV in oral can-
cer, we studied the DNA binding activity and expression pattern
of NF-jB family of proteins in different stages of oral cancer and
correlated with HPV infection that has been associated with bet-
ter prognosis of the disease. A total of 110 fresh oral tissue biop-
sies were collected comprising 10 normal controls, 34 precancer
and 66 oral cancer lesions prior to chemotherapy/radiotherapy.
Diagnosis of HPV was done by both consensus and type-specific
PCR. Electrophoretic mobility shift assays, western blots and
immunohistochemical analysis were performed to assess the
binding activity and expression pattern of NF-jB family of pro-
teins (p50, p65, p52, c-Rel, RelB and Bcl-3) in oral tissue biop-
sies. Twenty seven percent (18/66) of the oral cancer biopsies
showed the presence of HPV infection exclusively of high risk
HPV type 16, which was primarily associated with the well dif-
ferentiated squamous cell carcinomas (WDSCC). We observed a
high constitutive activation of NF-jB with concomitant upregu-
lated expression of all the NF-jB members in oral cancer tissues.
Expression of NF-jB components gradually increased as the se-
verity of lesion increased from precancer to invasive cancer.
NF-jB p50 was found to be the major DNA binding component,
which is indicative of homodimerization of p50 subunits. Inter-
estingly, in HPV16 infected oral cancers although p50 showed
high binding activity, p65 also showed a partial involvement as
evidenced in supershift assay. Both by western blotting and
immunohistochemistry, a differential overexpression and nu-
clear localization of p50, p65 and partially of Bcl-3 were
observed in HPV16 positive oral cancer patients that also showed
an over-expression of p21. We therefore, demonstrate a constitu-
tive activation and differential expression of NF-jB proteins,
which change as a function of severity of oral lesions during devel-
opment of oral cancer. The NF-jB DNA binding is primarily due
to homodimerization of p50 but infection of high risk HPV pro-
motes participation of p65 in NF-jB complex formation, leading to
heterodimerization of p50/p65. We propose that the involvement
of p65 in HPV infected oral cancer may be linked to improved dif-
ferentiation and better prognosis of the disease when treated.
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Oral Squamous Cell Carcinoma (OSCC) is the sixth most com-
mon cancer and accounts for approximately 5% of all malignant
tumors worldwide.1 In India and South East Asia OSCC is the most
common malignancy amounting upto 50% of all malignant tumors.2
Although most of the OSCC is attributed to smoking and alcohol
consumption, a significant proportion of oral cancers have been dem-
onstrated to contain anogenital HPV infection.3 The high risk HPV
type 16 tends to be the most predominant type detected in
oral cancer.3,4 Interestingly, HPV infected patients were found to
have better overall survival than those with HPV negative tumors5–8
and showed well-differentiated tumors.9 However, the mechanism(s)
by which HPV infection improves the overall survival/prognosis in
oral cancer is not yet clearly understood.
Dysregulation of NF-jB expression and its activation is frequently
observed in many cancers, such as colon,10 breast,11,12 pancreatic,13
leukemia,14 lymphoma,15 myeloma16 and cervical cancer.17
NF-jB also controls the expression of several genes that regu-
late cell cycle (cyclin D1), differentiation (p21Cip/Waf1), cell sur-
vival (Bcl-2, Bcl-xL, cIAP), growth factors (VEGF), cell adhe-
sion (VCAM, ECAM-1) and angiogenesis (MMPs).18,19 Constitu-
tive activation of NF-jB has been observed in some head and neck
cancer (HNSCC) cell lines.20 High risk HPV type 16 has also been
shown to modulate NF-jB activation and expression in different
cancers.21,22
The NF-jB/Rel superfamily of eukaryotic proteins is a group of
ubiquitously expressed, pleotropic, transcriptional regulators that
bind to selective 10 base pair conserved sequence motif 50GGGG
RNN YYC 30 (R5 Pu, Y5 Py, N5 any base) present in the regu-
latory regions of the wide arrays of different genes.23,24 There are
5 members in the mammalian Rel family that are classified into 2
categories. One group involves RelA (p65), RelB and c-Rel, which
are produced in their mature forms and do not require proteolytic
processing. The other category includes NF-jB1 (p105) and NF-
jB2 (p100), which require processing to produce the mature p50
and p52 proteins, respectively. The most abundant NF-jB dimer is
p50/RelA, which is bound to inhibitory protein IjB and retained in
the cytoplasm till its nuclear translocation mediated by the degra-
dation of IjB in response to various cellular signals. The distinct
combinations of NF-jB members confer the specificity to tissue-
specific and inducible gene activation25,26; e.g., p50/p50 dimers
display high affinity binding for many distinct jB motifs but pro-
vides a strong transcriptional activation only when adopting a spe-
cific conformation induced by only a few jB motifs that have been
shown to be present in a limited number of genes such as TNFa,
MHC Class I and its own gene nf-kb1.27,28
In the present study we have analyzed the activation of NF-jB
and alterations, if any, in the expression of different NF-jB proteins
during oral carcinogenesis in vivo using tissue biopsies from
patients with precancerous and cancerous oral lesions. We demon-
strate the role of HPV infection on NF-jB trans-activation during
oral carcinogenesis and show why patients with HPV 16 positive
tumors seem to have a better prognosis and disease-specific sur-
vival, compared to HPV negative group.
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Material and methods
Tissue specimens
A total 110 oral tissue biopsies were collected comprising 66
patients with malignant and 34 with premalignant oral lesions and
10 normal healthy controls from the Department of ENT Surgery,
Lok Nayak Hospital, New Delhi. Informed consent was obtained
from all the patients and control subjects. The clinical characteris-
tics of these patients are presented in Table I. All the patients were
chosen prior to any chemotherapy or radiotherapy treatment.
Biopsy tissues were collected in sterile PBS. One half of the tis-
sues were immediately frozen in 270C and the remaining halves
were sent for histopathological diagnosis in formalin solution.
DNA extraction and diagnosis of human papillomavirus infection
High molecular weight genomic DNA was isolated from normal,
precancerous and cancerous oral biopsies by the standard phenol–
chloroform and proteinase K digestion procedure, and PCR amplifi-
cation was performed following the procedure described earlier.29
The initial diagnosis of human papillomavirus (HPV) was performed
by using a pair of consensus degenerate primers (MY09 and MY11)
derived from the highly conserved L1 open reading frame (ORF) of
viral genome (MY09:50-GCM CAG GGW CAT AAY AAT GG-30,
MY11:50-CGT CCM ARR GGAWAC TGA TC-30where M5 A/C;
W 5 A/T; Y 5 C/T; R 5 A/G). Further typing of high risk HPV
types 16 and 18 were done by type-specific primers [HPV16 – (1) 50-
AAG GCC AAC TAA TAG TCA C-30, (2) 50-CTG CTT TTA TAC
TAA CCG G-30; HPV18 – (1) 50-ACC TTA ATG AAA AAC CAC
GA-30, (2) 50-CGT CGT TTA GAG TCG TTC CTG-30]. PCR was
performed in a 25 lL reaction mixture containing 50–100 ng DNA,
10 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2,125 lM of
each dNTPs (dATP, dGTP, dCTP, dTTP), 5 pmol of oligonucleotide
primers and 0.5 U Taq DNA polymerase. b-globin gene was used as
internal control (1) 50-CAA CTT CAT CCA CGT TCA CC-30, (2)
50-GAA GAG CCA AGG ACA GGT AC-30). The temperature pro-
file used for amplification constituted an initial denaturation at 95C
for 4 min followed by 30 cycles of denaturation at 95C for 30 sec,
annealing at 55C for 30 sec and extension at 72C for 1 min, which
was extended for 5 min at the final cycle. The primers were synthe-
sized in an automated DNA synthesizer (Model 381A; Applied Bio-
systems, Foster City, CA) using phosphoramidite chemistry and puri-
fied in high pressure liquid chromatography (HPLC; LKT Pharmacia,
USA).
Preparation of protein extract
Protein extracts from all oral biopsies (precancer, cancer and
control) were prepared by the method of Dignam et al.30 with cer-
tain modification.31 Briefly, the method involved mincing of fro-
zen tissues and it was suspended in ice-cold buffer A [20 mM
HEPES pH 5 7.6, 20% (v/v) Glycerol, 10 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 1 mM DTT, 1 mM PMSF, 2 lg/ml Leu-
peptin and 10 lg/ml Aprotinin]. The lysates were microfuged at
4,000 rpm for 10 min at 4C after incubating them for 15 min on
ice. The supernatant was transferred in a new tube and designated
as cytoplasmic extracts. The pellet containing isolated nuclei was re-
suspended in the 2 times pellet amount of extraction buffer B [20 mM
HEPES pH 7.6, 25% (v/v) Glycerol, 500 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 1 mM DTT, 1 mM PMSF, 2 lg/ml Leupeptin and
10 lg/ml Aprotinin]. The extraction mixture was microfuged after
1 hr at 14,000 rpm at 4C for 25 min. The resulting supernatant was
designated as nuclear extract. The concentration of protein in the
extracts was determined by standard Bradford method and the
extracts were stored at270C freezer until use.
Electrophoretic mobility shift assay
To detect the NF-jB DNA-binding activity in the nuclear ex-
tracts, Electrophoretic mobility shift assay (EMSA) was performed
as described earlier17,31,32 using the following oligonucleotides: NF-
jB consensus sequence 50-AGT TGA GGG GAC TTT CCC AGGG
C-30 (consensus binding sites are underlined), Oct-1 50-TGT CGA
ATG CAA ATC ACT AGA A-30. The oligos were synthesized in
Applied Biosystems DNA synthesizer using phosphoramitide chem-
istry. These oligos were annealed and labeled with [g32P] ATP
(3,000 Ci/mmol, Jonaki, Hyderabad, India) by T4 polynucleotide ki-
nase and gel purified onto a 15% polyacrylamide gel. Briefly, a bind-
ing reaction of 10lg nuclear extract with [g32P] labeled oligo probe
was performed in a 25 ll reaction volume containing 50% Glycerol,
60 mM HEPES pH 7.9, 20 mM Tris-HCl pH 7.9, 300 mM KCl, 5
mM EDTA, 5 mM DTT, 100 lg/ml of bovine serum albumin, 2.5
lg of poly (dI-dC) for 30 min at room temperature. The DNA–pro-
tein complexes were resolved on 4.5% nondenaturing polyacryl-
amide gel (29:1 cross-linking ratio), dried and exposed overnight to
KODAK X-Omat films (Kodak India, India). Binding specificity was
evidenced by preincubation with a 100-fold molar addition of homol-
ogous unlabelled oligonucleotide of NF-jB and heterologous con-
sensus sequence of the Oct-1 transcription factor. For monitoring
composition of NF-jB complex by supershift assay, 2 lg of polyclo-
nal antibodies (Abs) directed against each NF-jB family member
(Santa Cruz Biotechnology, Santa Cruz, CA) were added and the
reaction mixture was further incubated for 1 hr at 4C. The rabbit
polyclonal antibodies against following NF-jB proteins were used:
p50 (epitope corresponding to NLS region of p50 of human origin),
p65 (epitope corresponding to amino terminus of p65 of human ori-
gin), p52 (epitope within a conserved domain of mouse origin), c-Rel
(epitope within the amino terminal domain of human origin), RelB
(epitope corresponding to carboxy terminus of mouse origin), Bcl3
(epitope corresponding to carboxy terminus of human origin). The
quantitative densitometric analysis was performed using Alpha Ease
FC version 4.1.0 (Alpha Innotech Corporation, IL).
SDS–Polyacrylamide gel electrophoresis and immunoblotting
Nuclear extracts (40 lg/lane) were separated in 10% polyacryl-
amide gel, electrotransferred to Immobilon-P, PVDF membranes
(Millipore Corporation, Bedford, MA), and probed with polyclo-
nal rabbit antibodies. The incubation was carried out overnight in
PBS supplemented with 5% skimmed milk powder, 0.05% Tween
20 (Sigma, St. Louis, MO) and 1:5,000 dilution of the respective
antibodies. The blots were washed, exposed to horseradish peroxi-
dase-conjugated anti-rabbit IgG secondary antibodies for 1 hr and
finally the bands were visualized by Luminol detection kit (Santa
Cruz Biotech). Samples were run several times to determine the
level of expression of different NF-jB proteins and every time
membrane was re-probed for b-actin expression as control. The
expression level of different NF-jB proteins was quantitated as
described earlier31 on an arbitrary scale where Strong5 þþþþ;
Medium 5 þþ; Weak 5 þ; and Nil/not detectable 52.
Immunohistochemistry
The Immunohistochemical staining was performed on 5 lm
thick paraffin embedded tissue sections. Slides were deparaffi-
nized in xylene twice for 30 min and rehydrated through gradual
TABLE I – CLINICOPATHOLOGICAL CHARACTERISTICS WITH THE SITES
OF TISSUE RECOVERY OF PATIENTS AND HEALTHY CONTROLS
RECRUITED FOR ORAL TISSUE BIOPSY STUDY
Characteristics Normal PCL OCL
Number of biopsies 10 34 66
Mean age (years) 45.46 15.5 48.26 9.7 52.9 6 10.8
Male:female ratio 4:1 7.5:1 6.3:1
Tumor Sites
Tongue 4 14 36
Mandibular gingiva 1 4 7
Maxillary gingiva 0 3 4
Buccal mucosa 3 6 12
Palate 0 2 3
Lips 2 5 4
The numbers indicate total cases in each category. PCL: precancer-
ous lesions consists of hyperplastic and dyplastic lesions including
leukoplakia. OCL: oral cancer lesions.
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addition of ethanol solution to distilled water. Heat-induced epitope
retrieval was carried out by microwave treatment in the 10 mM
citrate buffer (pH 6.0). Endogenous peroxidase activity was
quenched by 3% H2O2. Nonspecific binding site was blocked using
1.5% blocking serum (ABC staining kit, Santa Cruz Biotech)
diluted in Tris-buffered saline (TBS). Tissue sections were incu-
bated with rabbit antibody diluted to 1:50 at 4C in a humidified
chamber for overnight, followed by biotinylated secondary antibody
(1:200 dilution) from ABC staining kit (Santa Cruz Biotech). The
peroxidase-labeled streptavidin antibody was added from the same
staining kit and incubated in the similar incubation conditions. Finally
3,30-Diaminobenzidine (DAB) was used as the chromogen in pres-
ence of hydrogen peroxide. Counterstaining of nuclei was done using
Meyer’s Hematoxylin. Intensity scoring of expression of assessed
proteins in immunostained preparations was performed using a arbi-
trary semiquantitative scale: none (2); low (þ); moderate (þþ) and
high (þþþþ).
Results
To study the expression and activation of different members of
NF-jB transcription factor during oral carcinogenesis and their
modulation following HPV infection, biopsy specimens (n 5 110)
were collected from histologically proven normal (n5 10; negative
for HPV infection), oral precancer (n 5 34) and cancer (n 5 66)
patients displaying tumors at different sites of the oral cavity as
indicated in Table I. Mean age (6 SD) and Male:Female gender ra-
tio varied from 45.4 6 15.4 years and 4:1 in control subjects,
48.2 6 9.7 years and 7.5:1 in precancer and 52.9 6 10.8 years and
6.3:1 in cancer patients, respectively. The presence of HPV infec-
tion and their type specificity were determined by PCR.
Detection of HPV DNA sequences in oral tissue biopsies
To detect HPV infection in the oral biopsies, total genomic DNA
was isolated and PCR amplification of L1-conserved sequence was
performed using consensus primer as described earlier.29 Type-spe-
cific primers were further used to diagnose presence of high risk
HPV types 16 and 18. The prevalence of total HPV was found to be
22% (22/100) while frequency of high risk type 16 was 18%
TABLE II – HPV DIAGNOSIS AND PATHOLOGICAL GRADES OF ORAL
BIOPSIES ANALYZED
Category Grades No. of cases HPV positivity1 HPV162
A Normal/control 10 – –
B Precancerous 34 4 (12) –
Leukoplakia 4 – –
Erythroplakia 1 – –
Hyperplasia 9 1 (3) –
Dysplasia 20 3 (9) –
C Cancerous 66 18 (27) 18 (100)
WDSCC 39 12 (18) 12 (66)
MDSCC 18 4 (6) 4 (22)
PDSCC 9 2 (3) 2 (11)
HPV; Human Papillomavirus, WDSCC; well-differentiated squa-
mous cell carcinoma, MDSCC; moderately-differentiated squamous
cell carcinoma, PDSCC; poorly-differentiated squamous cell carci-
noma. Values in parentheses are in percentages.
1Percent distribution of HPV infection in different grades of pre-cancer
or cancer cases with respect to total cases in each category. 2Percent dis-
tribution of high risk HPV type 16 in different grades of cancer cases
with respect to total HPV-positive cancer cases.
FIGURE 1 – (a). Constitutive NF-
jB activation in malignant oral biop-
sies. Gel shift analysis using nuclear
extracts from the different grades of
oral tissue with 32P-labelled NF-jB
oligonucleotide probe. Oral cancer
lesion (OCL) shows NF-jB binding
activity. (b) Binding of NF-jB to
DNA probe is sequence-specific.
Binding specificity was evidenced
using nuclear extracts (10 lg) pre-
pared from oral cancer biopsies were
incubated with unlabelled 100 M ex-
cess of specific competitor (NF-jB)
probeincomparisionwithcompetition
experimentusingnonspecificcompeti-
tor (Oct-1) and then checked for spe-
cific NF-jB binding by EMSA.
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(18/100) but we did not detect any HPV18 DNA sequences. The
majority of cancer cases (48/66, 72.7%) were found to be negative
for HPV infection. The high risk HPV type 16 was detected only in
patients with oral cancer (18/66, 27.3%; Table II). Among different
grades of oral cancers, majority (12/66, 18%) of the HPV infection
was seen in well differentiated squamous cell carcinoma (WDSCC)
followed by 6% (4/66) in moderately differentiated carcinoma
(MDSCC) while the least positivity (2/66, 3%) for HPV DNA was
detected in PDSCC cases. Out of 34 precancerous biopsies compris-
ing leukoplakia, erythroplakia, and hyperplasia only 4 (11.7%)
showed the presence of HPV infection (one HPV type 11 and three
HPV type 6) but no high risk HPVs could be detected in any of
these lesions. All the 10 normal healthy controls did not show posi-
tivity for any HPV DNA sequence.
Constitutive activation of NF-jB in oral cancer
The relative DNA binding activity of NF-jB was determined
during the progression of oral cancer by electrophoretic mobility
shift assay (EMSA) with the nuclear extract prepared from tissue
specimens collected from biopsy of normal, precancerous (PCL)
and cancerous lesions (OCL) and 32P-labeled probe harboring NF-
jB consensus sequence. Malignant oral tissues showed a signifi-
cantly higher DNA binding activity of NF-jB while absence or
very low binding was found in normal as well as in the precancerous
lesions. The nuclear extracts from normal healthy controls (n 5 10)
showed least or no DNA binding activity for NF-jB cognate
sequence (Fig. 1a). The binding activity of NF-jB showed a gradual
increase with the increasing severity of oral lesions. The binding
specificity of NF-jB to DNA was confirmed by competition assay
FIGURE 2 – Increased expression of p65, p50, p52, RelB and c-Rel in oral cancer lesions. (a) A total of 40 lg protein extracts each from normal,
precancerous (PCL) or oral cancer lesions (OCL) biopsies from HPV-negative cases were separated on a 10% SDS-PAGE, electrotransferred on
PVDF membrane and probed for p65, p50, p52, RelB or c-Rel expression. To confirm equal protein loading, the membranes were reprobed for
b-actin expression. (b) Immunohistochemical analysis of normal, precancerous (PCL) and cancerous (OCL) oral tissue from HPV-negative cases
for expression of different NF-jB members. Paraffin embedded (5 lm) oral tissue sections of normal mucosa, precancerous lesion and oral cancer-
ous lesion were probed with antibodies against p50, p65, p52, c-Rel and RelB to perform immunohistochemical analysis as described in Methods
(Original magnification: 2003). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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using a 100 fold molar excess of cold, specific competitor probe of
NF-jB and nonspecific competitor, a heterologous probe of tran-
scription factor Oct-1. The retarded complex of DNA-protein disap-
peared when the nuclear extract was incubated with excess of cold
oligos of NF-jB but reappeared after its incubation with nonspecific
probe harboring consensus sequence for Oct-1 (Fig. 1b).
NF-jB family proteins show differential expression pattern
during oral carcinogenesis
Western blotting and immunohistochemistry experiments were
performed to analyze the level of expressions of all the NF-jB
family members, e.g., p50, p65, p52, c-Rel and RelB, during pro-
gression of oral cancer. In the western blotting p50, p65 and c-Rel
proteins showed a distinct gradual upregulation with the increasing
severity of the lesion. p50 protein was found to be highly expressed
in all malignant tissues but to a moderate level in precancerous
lesions (Fig. 2a and Table III). A low expression of p50 protein was
observed in all the normal healthy subjects. The expression pattern
of p65 showed similar increasing trend with progression of lesion as
of p50 but to a much lesser extent. While a minor difference was
observed in the expression levels between pre-cancer and cancer for
p65 protein, its level was significantly elevated when compared to
those of normal healthy controls. Interestingly, c-Rel showed almost
a negligible expression in normal healthy controls but a very distinct
gradual increase was seen as the lesions progressed towards malig-
nant changes (Fig. 2a, lower panel). RelB protein expressed almost
uniformly in all grades of oral tissues from normal, premalignant to
malignant lesions but certain inconsistency was also observed in
some cases. The p52 protein expression also showed the similar
severity-dependent trend and elevated to the maximum in cancerous
tissues. The expression profile of NF-jB components was further
checked in situ by immunohistochemistry method in paraffin em-
bedded tissue sections. Intensity scoring of expression of NF-jB
proteins in immunohistochemistry preparations was performed on
an arbitrary four point scale; none (2); low (þ); moderate (þþ)
and high (þþþþ). The results correlate very much with those
obtained in western blotting analysis (Fig. 2b and Table IV).
Expression of p50 protein was either nil or low in all the normal tis-
sue sections examined, whereas 40% precancerous biopsies (8/20)
and 70% tumors (14/20) showed a moderate to a high expression of
p50. Remaining 30% of cancer cases (6/20) showed weak immunor-
eactivity for p50 antibody. Most of the normal oral mucosa showed
nil to moderate expression for p65 protein while only 20% of cancer
(5/20) and 30% of precancerous tissue showed strong positivity for
p65 protein expression and that too of low to moderate scale
(Fig. 2b). 85–90% of the cancer tissue sections showed moderate to
high staining for c-Rel (18/20) and RelB (17/20) proteins. Moderate
to high immunoreactivity for p52 protein was also visualized in
70% of cancerous cases (14/20) while its expression were either nil
or low in normal as well as precancerous mucosa (Table IV).
High risk HPV infection alters composition of NF-jB complex
during DNA-binding activity of NF-jB in malignant oral tumors
To examine the effect of high risk HPV infections on the NF-
jB DNA binding activity in malignant oral tumors, we compared
the NF-jB activity of nuclear extracts from HPV16 positive as
well as HPV negative oral tissue samples as depicted in Fig. 3a.
There was only a minor difference in the binding activity of
NF-jB between HPV positive and HPV negative oral cancers;
HPV positive cancers had a bit lower binding activity. However,
when the composition of NF-jB complex was further analyzed
using specific antibodies raised against different members of NF-
jB family, i.e., p50, p65, c-Rel, RelB, and p52, by supershift
assay, we did observe a differential binding pattern of these com-
ponents between HPV positive and negative oral cancer cases
(Fig. 3b). Although, p50 was the major binding component in both
HPV positive and negative oral cancer biopsies, addition of anti-
p65 also showed a minor shift in only HPV positive biopsies but it
is absent in HPV negative cases. Almost negligible shift was ob-
served for other members of NF-jB family in both, HPV16 posi-
tive and negative biopsies.
Since Bcl-3 protein of IjB family is known to co-exist/co-pre-
cipitate with p50/p50 homodimer and act as a co-activator of p50/
p50-mediated transcription,33 we checked the presence of Bcl-3 in
DNA-binding activity of NF-jB complex. Addition of anti-Bcl-3
antibody resulted in diminished NF-jB-DNA binding activity in
both HPV negative and HPV positive malignant biopsies in the
supershift assay; however, the effect was higher in the HPV nega-
tive oral cancer lesions (Fig. 3b, Last lanes). Despite the absence
of supershifted bands which could be due to interaction of Bcl-3
antibody with DNA binding motif of p50/p50/Bcl-3 complex, the
diminished binding is indicative of interaction between Bcl-3 and
p50 leading to p50:p50 homodimerization during oral carcinogen-
esis. As the involvement of Bcl-3 is lesser in HPV positive cancer,
it appears that the p50/p50 homodimer is stoichiometrically lesser
in the DNA binding activity in HPV positive cancer which also
contains conventional p50/p65 heterodimer.
Expression dynamics of NF-jB protein members and Bcl-3
are different in the high risk HPV infected oral cancer lesions
The expression pattern of all members of NF-jB/Rel family of
proteins including Bcl-3 was comparatively analyzed in both
TABLE III – EXPRESSION OF NF-jB PROTEINS IN NORMAL ORAL MUCOSA, PRECANCEROUS AND CANCEROUS ORAL LESIONS1
Proteins
Normal (n 5 10) Precancerous lesions (n5 34) Cancerous lesions (n5 66)
Nil Weak Medium Strong Nil Weak Medium Strong Nil Weak Medium Strong
P50 – 1 8 1 – 5 20 9 – 2 24 40
P65 1 4 5 – 2 4 23 5 – 6 39 21
P52 2 3 5 – 3 5 22 4 – 7 39 20
cRel 8 2 – – 1 6 16 11 – 2 19 45
RelB – 2 6 2 – 2 22 10 – 2 43 21
1Arbitrary level of expression in immunoblotting: Strong, þþþþ; Medium, þþ; Weak, þ; Nil/not detectable, –.
TABLE IV – EXPRESSION OF NF-jB SUPERFAMILY MEMBERS IN
DIFFERENT GRADES OF ORAL TISSUE BIOPSIES
NF-jB
proteins
Histological
grades
Level of Expression
2 (None) þ (Low) þþ (Moderate) þþþþ (High)
p50 NM 8 2 0 0
PCL 10 2 5 3
OCL 2 4 6 8
p65 NM 7 2 1 0
PCL 13 2 4 1
OCL 12 2 3 3
p52 NM 7 2 1 0
PCL 5 5 4 6
OCL 1 5 7 7
c-Rel NM 8 1 1 0
PCL 7 3 4 6
OCL 0 2 8 10
RelB NM 5 2 2 1
PCL 5 4 4 7
OCL 0 3 8 9
Normal mucosa (NM, n 5 10), precancerous Lesions (PCL, n 5 20),
oral cancer Lesions (OCL, n 5 20). The values indicate the distribution
of specimens in each category.
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HPV16 positive and HPV negative oral tumor biopsies by western
blotting. The results showed an increased expression of p50 and
Bcl-3 in HPV16 positive oral cancer cases as compared to that of
HPV negative cancers (Fig. 4a and Table V). HPV 16 infected
oral cancer lesions (OCL) also showed a marginal increase in the
expression level of p65 protein. But there was no difference in the
expression of c-Rel, RelB and p52 proteins in the HPV infected
malignant tissues when compared to those were negative for HPV
infection.
These results were further re-examined by immunohistochemical
staining of tumor tissue sections from HPV 16 positive and HPV
negative oral cancer cases with the antibodies of p50, p65 and
Bcl-3 proteins. Figure 4b shows presence of koilocytes in HPV pos-
itive tissue sections which clearly indicate persistent HPV infection
in these cancerous biopsies and they showed an increased expres-
sion of p50 as well as Bcl-3 proteins. A moderate increase in the
level of p65 positivity was also observed in the HPV infected oral
cancer tissue when compared to HPV negative ones. p50, p65 and
Bcl-3 proteins were found to be evenly localized in the cytoplasm
as well as in the nucleus of the oral cancer lesions (Fig. 4b).
p21WAF protein is over expressed in well differentiated
squamous cell carcinoma
Since HPV16 positive oral lesions showed better differentiation,
the expression of NF-jB-regulated differentiation marker, p21,
was examined in different grades of oral cancer and compared
between HPV negative and HPV16 positive cases (Fig. 5). Normal
oral epithelium expressed very low but detectable level of p21.
However, a very high expression of p21 was observed in well dif-
ferentiated oral cancer. The poorly and moderately differentiated
lesions showed low and moderate p21 expression respectively.
Interestingly, the level of p21expression in HPV16 positive lesions
was similar or slightly higher to the level observed in respective
grades of HPV-negative well differentiated squamous cell carci-
noma (WDSCC) and PDSCC lesions.
Discussion
In the present report, we show that a significant proportion of
oral cancer patients harbor only high risk HPV types 16, which is
highest in the well-differentiated squamous cell carcinomas. We
observed a constitutive activation of transcription factor NF-jB
which is accompanied by a generalized increase in the expression
of all the members of NF-jB family proteins during development
of oral cancer as revealed by western blotting and immunohisto-
chemical analysis carried out in freshly collected oral tissue biop-
sies. We also report here that in oral squamous cell carcinoma,
NF-jB complex is primarily of p50 protein which appears to form
a p50/p50 homodimer. Although the extent of NF-jB DNA bind-
ing activity remains a bit lower in the HPV infected oral cancer
tissue, a partial involvement of p65 in NF-jB complex is observed
in these cases only as revealed by supershift assay of nuclear
extracts as well as by immunohistochemistry. In the present inves-
tigation, we have tried to find a correlation between NF-jB DNA-
binding activity, its composition and, expression and HPV infec-
tion during oral carcinogenesis.
Primary screening to detect total positivity for HPV DNA
sequences in precancerous and cancerous lesions revealed 22% of
oral tissue biopsies positive for HPV L1 consensus sequence with
majority of infection in cancerous lesions and that too only of high
risk HPV type 16 (18%). These results are in good agreement with
earlier reports which showed that HPV positivity rate varies
FIGURE 3 – Effect of high risk HPV type 16 infection on constitutive NF-jB activity and its composition in oral cancer lesions. (a) Nuclear
extracts (10 lg) prepared from normal, precancerous (PCL) and cancerous (OCL) oral biopsies without HPV infection (HPV2) or with HPV
type 16 infection (HPVþ) were checked for NF-jB binding activity by EMSA as described in Methods. (b) High risk HPV type 16 infection
results in alteration of DNA binding pattern of NF-jB members in oral cancer lesions. Nuclear extracts (10 lg) prepared from HPV2 OCL and
HPVþ OCL were incubated with specific antibodies (2 lg each) either against p50, p65, p52, c-Rel, RelB or Bcl-3 and assayed for NF-jB bind-
ing activity by EMSA as described in Methods and band intensities quantified are indicated.
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between 10–20% in oral cancers.4,8,34,35 These studies also found
HPV16 as the predominant HPV type as observed by us in oral
squamous cell carcinomas. Interestingly, in India HPV type 16 has
been found to be almost exclusively prevalent in cervical squa-
mous cells carcinoma36 andenocarcinoma of the cervix37 and
bladder cancer38 but not in lung cancers, which harbor only
HPV18 DNA sequences.39 However, some authors have reported
higher HPV prevalence and occurrence of other high risk HPV
types in oral cancer from other regions of India.34,40–42 These var-
iations may be due to geographical and ethnic differences or selec-
tion bias for recruiting only betel quid chewing or tobacco smok-
ing oral cancer patients and varied PCR protocols and primers
used by different investigators.
In the present study, we found a strong NF-jB DNA-binding
activity contributed by p50/p50 homodimer in oral cancer, which
was absent in normal mucosa. An aberrant expression of NF-jB
proteins is well documented in other cancers.43,44 There are
reports indicating a constitutively activated NF-jB in epithelial
cell carcinomas similar to our observations, however, the compo-
sition of NF-jB complex was strikingly different and the DNA-
binding activity was predominantly due to conventional p50/p65
heterodimer.20,45 This dissimilarity clearly shows a different com-
position of NF-jB compared to what we found in an in vivo situa-
tion where DNA-binding is primarily due to p50/p50 homodimer
in fresh oral cancer biopsies. In agreement with our observation,
Budunova and his colleagues46 have also described a constitutive
activation of NF-jB in a mouse skin carcinogenesis model and
showed that the complex that binds jB sequence is a p50/p50
homodimer. Since composition of NF-jB regulates the transcrip-
tional specificity,24,26 it is quite likely that p50/p50 homodimer
mediated NF-jB activity provides a better survival and prolifera-
tive advantage to the tumor cells than the canonical p50/p65 form
in oral carcinogenesis. P50 homodimers transcriptionally regulate
antiapoptotic Bcl-2,47 which has been shown to overexpress in
high proportions of oral cancer cells,48,49 and to inhibit terminal
differentiation of oral keratinocytes.50 Since Bcl-2 expression is
FIGURE 4 – Upregulation of p65, p50 and Bcl-3 expression in HPV16 infected oral cancer lesions. (a) A total of 40 lg protein extracts each from normal,
HPV negative (HPV2) oral cancer lesions (OCL) and HPV16 positive oral cancer lesion (HPVþ OCL) biopsies was separated on a 10% SDS-PAGE, electro-
transferred on PVDFmembrane and probed for p65, p50, p52, RelB, Bcl-3 or c-Rel expression. To confirm equal protein loading, the membranes were re-probed
for b-actin expression. (B) Comparative immunohistochemical analysis of HPV2 OCL and HPVþ OCL for expression of canonical NF-jB members. Paraffin
embedded sections of indicated tissues were probed with antibodies against p50 and p65 and Bcl-3. Immunohistochemical analysis was performed as described
inMethods. (Original magnification: 2003). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
TABLE V – EXPRESSION OF NF-jB PROTEINS IN NORMAL ORAL MUCOSA AND HPV16 POSITIVE AND
HPV NEGATIVE ORAL CANCEROUS LESIONS (OCL)1
Proteins
Normal (n 5 10) HPV-negative OCL (n 5 48) HPV16-positive OCL (n5 18)
Nil Weak Medium Strong Nil Weak Medium Strong Nil Weak Medium Strong
P50 – 1 8 1 – 2 22 24 – – 2 16
P65 1 4 5 – – 4 32 12 – 2 7 9
P52 2 3 5 – – 3 31 14 – 4 8 6
cRel 8 2 – – – 2 14 32 – – 5 13
RelB – 2 6 2 – 1 32 16 – 1 11 5
Bcl–3 2 6 2 – – 5 31 12 – 2 12 5
1Arbitrary level of expression in immunoblotting: Strong, þþþþ; Medium, þþ; Weak, þ; Nil/not detectable, –.
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independent of IKK/p65 activation,51 it provides a selective sur-
vival and proliferative advantage to oral keratinocytes.
The exact mechanism by which NF-jB is constitutively acti-
vated in oral carcinoma cells is not yet fully understood but it has
been suggested that autocrine expression of IL-1 and EGFR may
play an important role in the activation of NF-jB.52,53 Chromatin
immunoprecipitation studies have demonstrated that p50 homo-
dimer along with Bcl-3 binds to NF-jB consensus motifs within
egfr promoter in nasopharyngeal carcinoma.54 Some reports have
indicated that the enhanced binding activity may be due to in-
creased IKK and PI3 Kinase activity in oral cancer.55,56 However,
recent reports indicate that only PI3 Kinase/MEK/ERK is in-
volved,51,57 but IKK activity may not be required for the high
binding activity of p50 homodimer.51,58
In our immunohistochemistry study the most intriguing observa-
tion is the presence of highly widespread koilocytes (see Fig. 4b) in
the oral carcinoma cells. In cervical carcinoma, infection by a high-
risk HPV type is an absolute requirement for malignant progression4
whereas in oral cancer it is not. Thus, the cervical carcinoma cells
are known to be the most suitable host for infection by this subset of
genital HPVs than are normal oral keratinocytes. However, during
progression of cervical lesions koilocytes can only be seen in HSIL
and sometimes in carcinoma cells and these are certainly not as
widespread as seen in oral carcinomas. This is indicative of an inter-
esting finding that oral carcinoma cells are fully capable of support-
ing productive HPV infection. This needs further investigation.
Both immunoblotting and immunohistochemistry data demon-
strate a differential increase in the expression of all the members
of NF-jB family proteins during development of oral cancer with
most remarkable increase in p50 and c-Rel expression. A signifi-
cant increase of p50 expression has been shown to occur during
murine oral carcinogenesis.46 Similar increased expression of p50
has been recently observed in human cervical carcinoma.17
Among the genes which are known to be positively regulated by
p50/p50 homodimers are TNFa, MHC Class I and its own gene
NF-jB1.27,28,59 Thus it is very likely that oral neoplastic cells hav-
ing constitutively active p50/p50 homodimers positively regulate
the p50 expression and show highly increased p50 protein. Simi-
larly, we also observed consistently a gradual increase in c-Rel
expression during progression of oral lesions. c-Rel has been dem-
onstrated to control epidermal development and homeostasis in
embryonic and adult skin.60 The overexpression of c-Rel has been
implicated in hematopoietic and solid malignancies as well.61–63
Our observation along with these data, strongly support an impor-
tant role of c-Rel in oral carcinogenesis. However, our supershift
assays failed to show its involvement in NF-jB DNA-binding
activity. Thus, no correlation was observed between increased
expressions, it’s nuclear accumulation and participation in DNA-
binding activity, and clinical outcome indicating that c-Rel is ei-
ther not a functional target for oral carcinogenesis or it acts thor-
ough some other mechanism yet to be identified.
In contrast to p50 and c-Rel, available literature on p65 expres-
sion indicates contradictory reports. Either no change46 or mild64
or even high expression of p6555,65 in different oral cancer model
systems have been reported. We find only a small proportion of
cancer and precancerous lesions express moderate to high level of
p65, but majority of lesions show a very low expression of p65
that too localized in the cytoplasm. Therefore, p65 even though
present in the cancer cells does not take part in NF-jB complex
formation in HPV negative oral cancers and hence it is unlikely to
play a significant role in transcriptional regulation during oral tu-
morigenesis. Interestingly, our supershift assay and immunohisto-
chemistry analysis demonstrate for the first time a partial nuclear
involvement of p65 in NF-jB complex formation only in HPV16
positive oral cancer.
Activation of NF-jB is a hallmark of most viral infections.
Viral infection directly or indirectly has been shown to activate ca-
nonical p50/p65 heterodimer in the NF-jB complex.66,67 Several
proteins encoded by p50/p65 target genes participate in the activa-
tion of host immune response.23 Our study indicates a small but
significant and consistent nuclear localization of p65 and its
involvement in DNA-binding activity in HPVþ oral cancer lesions
indicating host’s immune response to HPV infection. A functional
NF-jB binding site has been detected in HPV16 LCR region
which, if bound to p50/p65 heterodimer, acts as a transcriptional
repressor of HPV.19 However, as described by these authors, the
affinity of this site is much lower in comparison to consensus jB
promoter site. It was also observed that NF-1 binding site overlaps
this NF-jB site which upregulate the LCR activity.68,69 Thus, NF-
jB p50/p65 apparently possesses a negative regulatory activity
against HPV which p50/p50 homodimer does not execute due to
lack of transactivation domain. However, this phenomenon was
found limited only to infection by high risk HPV (HPV16) and
could not be seen in infections with low risk HPVs (HPV6 and 11)
which were found only in pre-cancerous lesions. This observation
also gains support from a previous report which demonstrated no
involvement of p65 in NF-jB complex in laryngeal papilloma
infected with HPV types 6 and 11.70
Along with an increased expression of most of the NF-jB mem-
bers, results show a small reduction in NF-jB DNA binding activity
despite the presence of p65 in the nuclei of HPV16þ oral cancer
lesions (Fig. 3). Similarly, an enhanced expression of the functional
components of NF-jB has been observed in HPV-infected tumor
and showed a highly reduced DNA-binding activity.71,72 To counter
the cellular immune response through p50/p65, HPV mediate sup-
pression of NF-jB activity by its E7 oncoprotein which supress
IKK activity,21 inhibit Type I Interferon signals and decrease the
expression of IFN inducible genes.21,71,73 On the other hand, E6 has
been shown to enhance the expression of p50 and its binding to NF-
jB consensus sequences71 and it reduces transcriptional activity of
p50/p65 by competitive inhibition.21,74 Interestingly, E5 and E7 also
inhibit the expression of MHC I proteins71 which facilitate immune
recognition through viral antigen presentation. In addition, HPV to
escape the immune recognition requires PI3 Kinase activation,75
which is an upstream activator of p50 homodimer.51,57 Therefore,
oral cancer cells provide appropriate environment for viral entry
and persistence of HPV infection. These observations can poten-
tially explain the productive viral infection as indicated by presence
of widespread koilocytes despite presence of activated p50/p65.
Although the sample size is much less to conclude, our data do
indicate a higher percentage of HPV16 positivity associated with
well-differentiated SCC than the moderately or poorly-differentiated
SCC which are more advanced stages of the disease and show poor
prognosis. With an exception of only one report,76 similar observa-
tions have also been made consistently in oral and other cancers
which showed better overall survival of HPV-infected patients than
those with HPV-negative tumors5–8 and they showed well-differenti-
FIGURE 5 – Expression of p21 protein during oral carcinogenesis
and effect of HPV infection. A total of 40 lg protein extracts each
from normal, HPV negative (HPV2) Well-Differentiated SCC, Mod-
erately-Differentiated SCC, Poorly-Differentiated SCC oral cancer
lesions and HPV16 positive Well-Differentiated SCC, Poorly-Differ-
entiated SCC oral cancer lesion (HPVþ) biopsies were separated on a
12% SDS-PAGE, electrotransfered on PVDF membrane and probed
for p21 expression. To confirm equal protein loading, the membranes
were re-probed for b-actin expression.
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ated tumors.9 We show for the first time an involvement of p65 in
the constitutively active NF-jB complex generated in HPV16þ
lesions. Since HPV infection positively correlates with better prog-
nosis of patients, we hypothesize that p65 participation in NF-jB
might contribute to more differentiated state of the carcinoma. How-
ever, the mechanism(s) underlying these observations has been
unclear as yet. It is interesting to note that NF-jB induces the
expression of p21Cip/Waf1, a cdk inhibitor which is intimately
involved in coupling growth arrest to cellular differentiation in nor-
mal epithelial cells.77,78 In addition, patients with p21Cip/Waf1 expres-
sion tend to have a better prognosis than those without in endome-
trial carcinomas.79 However, during HPV16 infection, E7 oncopro-
tein has been shown to uncouple cellular differentiation and
proliferation in human keratinocytes by abrogating p21Cip1-mediated
inhibition of cdk2, while differentiation mechanisms remain
intact80,81 (see Fig. 6). Our results also indicate an over-expression
of p21 in well-differentiated oral squamous cell carcinomas
(WDSCCs) which show better prognosis, whereas the levels of p21,
which is required for normal differentiation, was found to be low in
normal oral tissue. Since the protein is required only transiently, it is
likely that only a subset of cells are expressing p21 in normal tissue
in contrast to well-differentiated carcinomas which has constitutively
active NF-jB. p21Cip1 has been shown to be over-expressed in the
HPV infected laryngeal papillomas.70 However, we did not see any
change in the expression pattern between HPV negative and HPV16
positive oral carcinomas. Further studies are being carried out at our
laboratory to establish a correlation between p21 expression and
HPV infection in oral cancer.
In conclusion, we show for the first time that the expression of
NF-jB family of proteins along with constitutive activation NF-
jB complex of comprising mainly p50/p50 homodimers increased
as a function of severity of oral lesions during development of oral
cancer. Infection of high risk Human Papillomavirus (HPV) pro-
motes participation of p65 in the DNA binding activity. We pro-
pose a plausible pathway (see Fig. 6) wherein the involvement of
virus-induced host’s response activates p50/p65 NF-jB complex
formation, which promotes differentiation of oral neoplastic cells,
leading to better prognosis of the disease. Further investigations
are being aimed at establishing this hypothesis and to dissect out
the mechanism(s) involved in active human papillomavirus repli-
cation/transcription resulting in extensive koilocyte formation spe-
cifically in oral keratinocytes.
FIGURE 6 – Schematic presentation showing the role of NF-jB during progression of oral cancer lesions and its modulation by HPV16 infection. Con-
stitutive activation NF-jB with involvement of p65 in DNA-binding activity during HPV16-infection presumably increase the expression of p21Cip1,
which may be responsible for better differentiated state in HPV infected oral lesions and thus improves prognosis and the survival of the patients.
Key: h, MHC class I molecules; e, HPV proteins; Black arrows, nuclear translocation; Red arrows, Inhibition; Green arrows, activation; Vertical
arrows, increased expression.
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